Medical Device Cytotoxicity Testing Services Following ISO 10993-5

Why Companies Trust NAMSA

15K+

Cytotoxicity Tests Conducted Last Year

Board-Certified DaBT Toxicologists on Staff

800

Biological Evaluation Plans and Reports Prepared Last Year

Major US and EU Labs Performing ISO 10993 Testing

Cytotoxicity is the fundamental measure of a medical device’s biological safety. It evaluates whether a device’s materials, chemicals, or leachables are toxic to living cells, which is the cornerstone of the biological evaluation strategy mandated by regulators like the US FDA and EU Notified Bodies.

ISO 10993-5: Biological evaluation of medical devices – Part 5: Tests for in vitro cytotoxicity is the harmonized standard that defines the methods for this critical testing.

With labs in the US and Europe, NAMSA is equipped to provide rapid, compliant, and cost-effective cytotoxicity testing to accelerate your device development.

Your ISO 10993-5 Cytotoxicity Testing Options

We offer three validated methods to definitively determine the safety of your device and materials. The choice of method depends on your device’s material type, porosity, geometry, and intended clinical use. Our Principal Toxicologists can help you select the most appropriate test to meet regulatory scrutiny while minimizing sample preparation and turnaround time.

NAMSA’s Core Cytotoxicity Methods

Method	Principle	Ideal Device Type	Regulatory Benefit
1. Elution Test (Extract Test)	Most Common & Sensitive. Device is incubated in a fluid (extract) that simulates body conditions. The extract is then applied to cells, and cell viability is measured.	Any non-porous or finished device, especially those with small surface areas (e.g., Catheters, Stents, Tubing).	Best for detecting leachable chemicals from the material or manufacturing process (e.g., sterilization residuals).
2. Direct Contact Test	The finished device material (or a piece of it) is placed directly onto a layer of cells.	Devices made of flexible or sheet-like materials (e.g., Dressings, Films, Soft Polymers).	Ideal for evaluating direct material toxicity and potential cellular damage from material contact.
3. Agar Diffusion Test (Overlay Test)	A layer of nutrient agar separates the cells from the test material. Toxic components must diffuse through the agar to reach the cells.	Dense materials or materials that may be difficult to extract (e.g., Elastomeric, Opaque, or Implantable materials).	Useful for materials where direct contact might physically harm the cells, ensuring only chemical effects are measured.

Take the Next Step

Don’t risk delays due to incomplete or poorly justified cytotoxicity data. Leverage NAMSA’s integrated approach to move confidently toward market clearance.

Schedule a Consultation

Why NAMSA for Medical Device Cytotoxicity Testing?

Cytotoxicity testing is a high-volume, mandatory requirement, and choosing the right partner impacts your project timeline and budget. NAMSA offers unmatched expertise and efficiency.

Risk-Based Strategy Integration: We view cytotoxicity not as a standalone test, but as the initial checkpoint in your broader Biological Evaluation Plan (BEP). Our experts ensure the results guide subsequent chemical and biological testing needs, often preventing unnecessary, more expensive in vivo studies.
Worst-Case Scenarios: Our protocols are designed to simulate worst-case clinical use, including using the final sterilization process (e.g., EtO, Gamma) on the test articles, a critical regulatory requirement.
Rapid Turnaround: With our state-of-the-art global laboratories, we provide some of the fastest turnaround times in the industry without compromising the quality or compliance of your data.

Integrating Cytotoxicity with Your Regulatory Submission

A successful cytotoxicity result is the key to unlocking the rest of your biocompatibility package. If a device fails this initial screening, the regulatory pathway will halt, requiring material changes and re-testing.

NAMSA ensures your cytotoxicity data seamlessly integrates with your overall submission strategy:

Material Characterization: Cytotoxicity results are often cross-referenced with ISO 10993-18 chemical characterization data to identify the exact leachable chemical compounds (e.g., residuals) causing cellular toxicity.
Toxicological Risk Assessment (TRA): Our Board-Certified Toxicologists use passing or negative cytotoxicity data to support the TRA, which is a major component of the final Biological Evaluation Report (BER).
Global Acceptance: Data generated in our labs is submitted to regulatory bodies worldwide, streamlining your global market clearance process.

Frequently Asked Questions (FAQs)

Cytotoxicity is the fundamental biological test that determines if a medical device material is toxic to living cells. It is the initial and most sensitive screening test required for virtually every device that touches the patient (internally or externally), as mandated by ISO 10993-1. It’s the first step because if a material shows cellular toxicity, it almost certainly poses an unacceptable biological risk and must be redesigned or re-evaluated before any further, more expensive testing is conducted.

Nearly all medical devices that have direct or indirect patient contact require cytotoxicity testing, regardless of the duration of contact. This includes:

Surface-Contacting Devices: Bandages, electrodes, external probes.
External Communicating Devices: Catheters, breathing circuits, endoscopes.
Implant Devices: Stents, orthopedic implants, heart valves.

The only exceptions are typically devices with no patient contact or specific materials (like silicone) where a scientific rationale based on historical data can be used to justify a waiver.

The three main in vitro methods are:

Elution (Extract) Test: The device is extracted in a fluid, and the fluid is applied to cells. This is the most common method because it effectively detects leachable chemicals (like manufacturing residuals or uncured monomers).
Direct Contact Test: A sample of the device material is placed directly on the cell monolayer.
Agar Diffusion (Overlay) Test: A layer of agar separates the material from the cells.

The Elution Test is generally considered the best and most widely applicable screening test for finished medical devices as it mimics the leaching of materials into body fluids. The appropriate test is always determined by the material properties and device geometry.

Yes, significantly. Sterilization processes, particularly Ethylene Oxide (EtO) or Gamma irradiation, can leave behind toxic residuals (like ethylene chlorohydrin or EtO gas) or alter the chemical structure of the device material. Therefore, the regulatory requirement is to test the final, finished device in its final sterilized state to ensure any processing residuals are evaluated in the cytotoxicity test.

A failed test means the device material or its leachables caused significant damage or death to the cells in the test system. This result typically halts the regulatory submission process.

A failure requires immediate action, usually involving one of the following:

Material Change: Substituting the material or component with one that is non-cytotoxic.
Process Change: Modifying the manufacturing process (e.g., curing time) or the sterilization cycle (e.g., increasing EtO aeration time) to reduce toxic residuals.
Further Analysis: Conducting Chemical Characterization (ISO 10993-18) to identify the exact toxic leachable and quantify its amount to see if a toxicological risk assessment can be performed.